Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology
Cytokinetics (NASDAQ: CYTK) announced its second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) scheduled for May 30th, 2025, at the Mission Bay Conference Center in San Francisco. The one-day symposium, running from 8:00 AM to 6:00 PM Pacific Time, aims to unite scientists, researchers, and emerging professionals in muscle biology.
The event will feature distinguished speakers including keynote speaker John C. Marioni from Genentech, alongside experts from prestigious institutions such as Stanford University, University of Pennsylvania, and University of British Columbia. Presentations will focus on innovations in cardiac biology, skeletal muscle biology, and emerging treatment modalities. The symposium will also include poster presentations of novel research.
Cytokinetics (NASDAQ: CYTK) ha annunciato il suo secondo simposio annuale Contemporary Landscapes in Muscle Biology Research (CLIMB), previsto per il 30 maggio 2025 presso il Mission Bay Conference Center di San Francisco. Il simposio di un giorno, che si terrà dalle 8:00 alle 18:00 ora del Pacifico, ha l'obiettivo di riunire scienziati, ricercatori e professionisti emergenti nel campo della biologia muscolare.
L'evento vedrà la partecipazione di relatori di spicco, tra cui il keynote speaker John C. Marioni di Genentech, insieme a esperti provenienti da istituzioni prestigiose come la Stanford University, l'University of Pennsylvania e l'University of British Columbia. Le presentazioni si concentreranno sulle innovazioni nella biologia cardiaca, nella biologia del muscolo scheletrico e sulle nuove modalità di trattamento emergenti. Il simposio includerà anche presentazioni poster di ricerche innovative.
Cytokinetics (NASDAQ: CYTK) anunció su segundo simposio anual Contemporary Landscapes in Muscle Biology Research (CLIMB), programado para el 30 de mayo de 2025 en el Mission Bay Conference Center de San Francisco. El simposio de un día, que se llevará a cabo de 8:00 a.m. a 6:00 p.m. hora del Pacífico, tiene como objetivo reunir a científicos, investigadores y profesionales emergentes en biología muscular.
El evento contará con destacados ponentes, incluido el orador principal John C. Marioni de Genentech, junto con expertos de instituciones prestigiosas como la Universidad de Stanford, la Universidad de Pennsylvania y la Universidad de British Columbia. Las presentaciones se enfocarán en innovaciones en biología cardíaca, biología del músculo esquelético y nuevas modalidades de tratamiento emergentes. El simposio también incluirá presentaciones de pósteres con investigaciones novedosas.
Cytokinetics (NASDAQ: CYTK)는 2025년 5월 30일 샌프란시스코 Mission Bay 컨퍼런스 센터에서 열리는 두 번째 연례 근육 생물학 연구 심포지엄인 Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB)을 발표했습니다. 오전 8시부터 오후 6시(태평양 표준시)까지 진행되는 하루짜리 심포지엄으로, 근육 생물학 분야의 과학자, 연구원 및 신진 전문가들을 한자리에 모으는 것을 목표로 합니다.
이번 행사에는 Genentech의 기조 연설자 John C. Marioni를 비롯해 스탠포드 대학교, 펜실베이니아 대학교, 브리티시 컬럼비아 대학교 등 명문 기관의 전문가들이 참여합니다. 발표는 심장 생물학, 골격근 생물학, 그리고 새로운 치료법에 관한 혁신적인 연구에 초점을 맞출 예정이며, 신기술 연구를 다룬 포스터 발표도 포함됩니다.
Cytokinetics (NASDAQ: CYTK) a annoncé son deuxième symposium annuel Contemporary Landscapes in Muscle Biology Research (CLIMB), prévu pour le 30 mai 2025 au Mission Bay Conference Center de San Francisco. Ce symposium d'une journée, qui se déroulera de 8h00 à 18h00 heure du Pacifique, vise à rassembler des scientifiques, chercheurs et professionnels émergents en biologie musculaire.
L'événement accueillera des intervenants de renom, notamment le conférencier principal John C. Marioni de Genentech, ainsi que des experts issus d'institutions prestigieuses comme l'Université de Stanford, l'Université de Pennsylvanie et l'Université de la Colombie-Britannique. Les présentations porteront sur les innovations en biologie cardiaque, en biologie musculaire squelettique et sur les nouvelles modalités de traitement émergentes. Le symposium comprendra également des présentations de posters sur des recherches novatrices.
Cytokinetics (NASDAQ: CYTK) hat sein zweites jährliches Symposium Contemporary Landscapes in Muscle Biology Research (CLIMB) angekündigt, das am 30. Mai 2025 im Mission Bay Conference Center in San Francisco stattfinden wird. Das eintägige Symposium, das von 8:00 bis 18:00 Uhr Pazifischer Zeit läuft, soll Wissenschaftler, Forscher und Nachwuchsexperten im Bereich der Muskelbiologie zusammenbringen.
Die Veranstaltung wird renommierte Redner umfassen, darunter den Hauptredner John C. Marioni von Genentech sowie Experten von renommierten Institutionen wie der Stanford University, der University of Pennsylvania und der University of British Columbia. Die Präsentationen konzentrieren sich auf Innovationen in der Herzbiologie, der Skelettmuskelbiologie und auf aufkommende Behandlungsmethoden. Das Symposium beinhaltet auch Posterpräsentationen neuer Forschungsarbeiten.
- None.
- None.
Second Annual Muscle Biology-Focused Research Symposium
Highlighting Recent Innovations in the Field
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30th, 2025 from 8:00 AM to 6:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA.
“CLIMB was born out of our vision to bring together key contributors in muscle biology across academia and industry to foster meaningful scientific exchange and showcase novel research,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As pioneers and leaders in muscle biology, we remain committed to advancing the field by deepening collective understandings underlying muscle-related diseases and disorders.”
CLIMB is an annual one-day research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the biological understanding and emerging treatment of muscle-related diseases and disorders. CLIMB will feature distinguished expert speakers alongside poster presentations of novel research in the field of muscle biology. Presentations will focus on innovations in cardiac biology, skeletal muscle biology and emerging treatment modalities in muscle biology. Expert speakers include:
- Keynote Speaker: John C. Marioni, Ph.D., Senior Vice President, Head of Computational Sciences, Genentech Research and Early Development
- Craig Blanchette, Ph.D., Senior Vice President, Head of Research, Switch Therapeutics
- Helen Blau, Ph.D., Donald E. and Delia B. Baxter Foundation Professor; Director, Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine
- Sharlene M. Day, M.D., Presidential Professor and Director of Translational Research, Division of Cardiovascular Medicine and Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine
- W. Michael Flanagan, Ph.D., Chief Scientific Officer, Avidity Biosciences
- Douglas Millay, Ph.D., Professor of Pediatrics, Division of Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati
- Fabio Rossi, M.D., Ph.D., Professor, School of Biomedical Engineering and Department of Medical Genetics, Scientific Director, BC Regenerative Medicine Initiative, University of British Columbia
- Robin M. Shaw, M.D., Ph.D., Director, Nora Eccles Harrison Cardiovascular Research and Training Institute, Professor of Medicine, University of Utah
- Jil C. Tardiff, M.D., Ph.D., Professor of Biomedical Engineering, Medicine, and Cellular and Molecular Medicine, University of Arizona
- Paul Titchenell, Ph.D., Executive Director, Metabolic Physiology, Eli Lilly and Company
Presenting research completed at the University of Pennsylvania Perelman School of Medicine
To attend CLIMB in person, register online by May 23, 2025, at https://climbsymposium.com/.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates and our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When and where is Cytokinetics (CYTK) hosting the CLIMB symposium in 2025?
Who is the keynote speaker at Cytokinetics' CLIMB 2025 symposium?
What is the focus of Cytokinetics' CLIMB 2025 symposium?
How can one register for Cytokinetics' CLIMB 2025 symposium?
